The Technical AnalystExchange: XETRA Sector: Pharmaceuticals Industry: Drug Manufacturers—Specialty & Generic
Merck KGaA Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.91% €150.30
Europe/Berlin / 2 mai 2024 @ 17:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 64 481 mill |
| EPS: | 6.49 |
| P/E: | 23.16 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 429.02 mill |
| Avg Daily Volume: | 0.274 mill |
| RATING 2024-05-02 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.70x |
| Company: PE 23.16 | sector: PE 33.16 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.59x |
| Company: PE 23.16 | industry: PE 39.15 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€89.09 (-40.73%) €-61.21 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
€ 147.31 - 154.69 ( +/- 2.44%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €150.30 (0.91% ) |
| Volume | 0.290 mill |
| Avg. Vol. | 0.274 mill |
| % of Avg. Vol | 105.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRK.DE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MRK.DE
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.